ZOLEDRONIC ACID IN BONE METASTASES FROM BREAST CANCER
- Authors: Snegovoy A.1, Kononenko I.1, Manzyuk L.1, Selchuk V.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 26, No 11 (2015)
- Pages: 62-65
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116445
- ID: 116445
Cite item
Open Access
Access granted
Abstract
The use of bone remodeling markers is of great importance for evaluating the efficiency of bone metastases in malignant tumors. It is a convenient and safe method that is essential for conducting clinical trials.
Keywords
Full Text
About the authors
A. Snegovoy
N.N. Blokhin Russian Cancer Research Center
Email: drsneg@gmail.com
Candidate of Medical Sciences
I. Kononenko
N.N. Blokhin Russian Cancer Research CenterCandidate of Medical Sciences
L. Manzyuk
N.N. Blokhin Russian Cancer Research CenterProfessor
V. Selchuk
N.N. Blokhin Russian Cancer Research CenterProfessor
References
- Kohno N., Aogi K., Minami H. et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastasis from breast cancer: a randomised, placebo-controlled trial // J. Clin. Oncol. - 2005; 23: 3314-21.
- Saad F., Gleason D., Murray R. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer // J. Natl. Cancer Inst. - 2004; 96: 879-82.
- Аполихин О.И., Сивков А.В., Ощепков В.Н. и др. Эффективность золедроновой кислоты у больных с костными метастазами рака предстательной железы. Приложение к журналу «Андрология и генитальная хирургия». Материалы Международного конгресса по андрологии 28-31 мая 2009. Сочи, ОК «Дагомыс» УД Президента РФ.
- Кулиева И.Э., Бесова Н.С. Опыт применения золедроновой кислоты (препарат Резорба) для лечения больных с костными метастазами // Эффективная фармакотерапия. Онкология, Гематология и Радиология. -2012; 4.
- Lipton A., Cook R., Major P. et al. Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity // The Oncologist. - 2007; 12: 1035-43.
- Seibel M., Lang M., Geilenkeuser W.-J. Interlaboratory Variation of Biochemical Markers of Bone Turnover // Clin. Chem. - 2001; 47: 1443-50.
- Leeming D., Koizumi M., Qvist P. et al. Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers // Biomarkers in Cancer. - 2011; 3: 15-23.
Supplementary files
